Literature DB >> 18772112

RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.

Kosei Ito1, Anthony Chee-Beng Lim, Manuel Salto-Tellez, Lena Motoda, Motomi Osato, Linda Shyue Huey Chuang, Cecilia Wei Lin Lee, Dominic Chih-Cheng Voon, Jason Kin Wai Koo, Huajing Wang, Hiroshi Fukamachi, Yoshiaki Ito.   

Abstract

In intestinal epithelial cells, inactivation of APC, a key regulator of the Wnt pathway, activates beta-catenin to initiate tumorigenesis. However, other alterations may be involved in intestinal tumorigenesis. Here we found that RUNX3, a gastric tumor suppressor, forms a ternary complex with beta-catenin/TCF4 and attenuates Wnt signaling activity. A significant fraction of human sporadic colorectal adenomas and Runx3(+/-) mouse intestinal adenomas showed inactivation of RUNX3 without apparent beta-catenin accumulation, indicating that RUNX3 inactivation independently induces intestinal adenomas. In human colon cancers, RUNX3 is frequently inactivated with concomitant beta-catenin accumulation, suggesting that adenomas induced by inactivation of RUNX3 may progress to malignancy. Taken together, these data demonstrate that RUNX3 functions as a tumor suppressor by attenuating Wnt signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772112     DOI: 10.1016/j.ccr.2008.08.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  101 in total

1.  RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines.

Authors:  Feng-Xian Zhai; Xiang-Fu Liu; Rui-Fang Fan; Zi-Jie Long; Zhi-Gang Fang; Ying Lu; Yong-Jiang Zheng; Dong-Jun Lin
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-18       Impact factor: 4.553

2.  RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.

Authors:  Mohd Feroz Mohd Omar; Kosei Ito; Min En Nga; Ross Soo; Bee Keow Peh; Tuty Muliana Ismail; Bhavin Thakkar; Richie Soong; Yoshiaki Ito; Manuel Salto-Tellez
Journal:  Pathol Oncol Res       Date:  2012-06-24       Impact factor: 3.201

3.  Tumor suppressor function of RUNX3 in breast cancer.

Authors:  Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

4.  Epigenetic changes induced by oxidative stress in colorectal cancer cells: methylation of tumor suppressor RUNX3.

Authors:  Kyoung Ah Kang; Rui Zhang; Gi Young Kim; Suk Chul Bae; Jin Won Hyun
Journal:  Tumour Biol       Date:  2012-01-25

5.  Taurine postponed the replicative senescence of rat bone marrow-derived multipotent stromal cells in vitro.

Authors:  Huijiao Ji; Guiyun Zhao; Jingfeng Luo; Xiaoli Zhao; Ming Zhang
Journal:  Mol Cell Biochem       Date:  2012-04-25       Impact factor: 3.396

6.  RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53.

Authors:  Chizu Yamada; Toshinori Ozaki; Kiyohiro Ando; Yusuke Suenaga; Ken-ichi Inoue; Yoshiaki Ito; Rintaro Okoshi; Hajime Kageyama; Hideki Kimura; Masaru Miyazaki; Akira Nakagawara
Journal:  J Biol Chem       Date:  2010-03-30       Impact factor: 5.157

Review 7.  Polycomb group proteins: navigators of lineage pathways led astray in cancer.

Authors:  Adrian P Bracken; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

8.  Placental DNA methylation alterations associated with maternal tobacco smoking at the RUNX3 gene are also associated with gestational age.

Authors:  Jennifer Z J Maccani; Devin C Koestler; Eugene Andrés Houseman; Carmen J Marsit; Karl T Kelsey
Journal:  Epigenomics       Date:  2013-12       Impact factor: 4.778

Review 9.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

10.  Runx3 expression in lymph nodes with metastasis is associated with the outcome of gastric cancer patients.

Authors:  Hong-Wei Xu; Feng Ren; Yan-Ming Yu; Cheng-Zhong Cai
Journal:  Oncol Lett       Date:  2011-08-11       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.